Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In an editorial commenting on the TOGETHER-PsO trial, Michael Garshick, MD, of New York University School of Medicine, New York, NY, and Joel Gelfand, MD, of University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, wrote, patients with psoriasis are up to 2-fold more likely to have obesity and that obesity increases the risk of psoriasis and psoriatic arthritis, is directly associated with more extensive skin involvement, and reduces response to treatment and increases loss of response to treatment over time. Ixekizumab is an IL-17 inhibitor that has shown deep and durable skin clearance with a well-established safety profile, with superiority against other biologic agents in psoriasis
The weekly injection day can be changed if at least 72 hours have elapsed since the last dose
[1] [2] Proper injection technique can reduce local reactions: Rotate injection sites among the abdomen, thigh, and upper arm to prevent localized sensitization Allow the medication to reach room temperature before injection (according to the Instructions for Use) [1] Use proper subcutaneous technique with appropriate needle angle Avoid injecting into areas with skin abnormalities, scars, or previous reaction sites Do not reuse needles or share pens between patients Note that upper arm injections may require administration by another person Patient education forms the cornerstone of safe use
1.0 / 3.0 = 0.333 mL x 100 = 33.3 units Round to 33 units
Signals that provoke thought rather than conclusions that close debate
The pre-filled, single-use pens are engineered to deliver precise doses and cannot be safely or accurately divided
